Navigation Links
PRA International Speaking Event: Beyond Global Feasibility
Date:3/19/2009

An Evidence-Based Approach to Creating Realistic Development Timelines

RALEIGH, N.C., March 19 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, announces its Senior Vice President of Scientific and Medical Affairs, Kent Thoelke, will host a webinar on optimizing site and country selection. The webinar will take place on March 25, 2009 at 11:30 am ET.

Mr. Thoelke will discuss how to mitigate one of the greatest risks for successful drug development: delayed clinical development timelines. Detailed planning and appropriate site and country selection are the most critical factors in meeting target patient accrual goals within the planned timeline. Mr. Thoelke will explore how an evidence-based approach, coupled with survey based feasibility provides the most accurate forecast for patient accrual and the selection of sites and countries with the highest likelihood of being productive.

With PRA since 2006, Mr. Thoelke has over 19 years of experience in the global drug development and device industry, holding positions in both clinical and corporate development in multinational R&D companies, as well as small and emerging biotechnology companies. As part of the PRA Leadership Team, Mr. Thoelke provides high-level strategic oversight of product development, supporting PRA teams that are executing studies for Sponsors. Having visited over 40 countries, he is very familiar with the global drug development environment, and has established relationships with therapeutic experts in numerous indications around the world. Mr. Thoelke has spoken widely regarding the current landscape of clinical trial recruitment and its effect on drug development timelines. He is active in pursuing novel technologies and strategies to move the current clinical drug development paradigm away from anecdotal strategy to a more focused evidence-based strategy.

The deadline for registration is Tuesday March 24, 2009. Registration information can be found at: http://www.fxconferences.com/Beyond-Global-Feasibility-An-Evidence-Based-Approach-to-Creating-Realistic-Development-Timelines-P300.aspx .

About PRA International

PRA International is a global Clinical Research Organization providing services through all phases of clinical development. Although we specialize in Oncology, CNS, Respiratory/Allergy, Cardiovascular and Infectious Diseases, we perform studies in all therapeutic areas. PRA has supported over 2,100 clinical trials through its 35 global offices. PRA's therapeutic expertise, global reach and project experience, combined with extensive local knowledge, enable our project teams to deliver consistent and on time performance for our clients.

To learn more about PRA International, please visit http://www.prainternational.com, email endpoints@praintl.com or call our Global Headquarters at +1 (919) 786-8200.


'/>"/>
SOURCE PRA International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Toxic Chemicals in Childrens Bath Products Trigger International Outcry
2. Barriers to diabetes care include restaurants and high-risk lifestyles, says international review
3. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
4. International Trachoma Initiative and the Task Force for Child Survival and Development Announce New Merger to Eliminate Blinding Trachoma and Fight Against Other Neglected Tropical Diseases
5. Mobile Massage Team Attending International Special Events Society Greater Philadelphia Chapter Industry Showcase - FRESH! 2009
6. Siemens to Donate Hearing Instruments Through Second Annual Partnership With Quota International
7. Relsys International Announces the Release of the Argus Safety(TM) Suite 5.0
8. DATATRAK International, Inc. Announces Fourth Quarter and Full Year Results for 2008
9. Irish-Owned Heritage Casket Company Strikes Multi-Million-Dollar Partnership Deal With Pennsylvanias Matthews International
10. AJWS Asks International Community to Demand Reinstatement of International Aid Groups Into Sudan
11. Clinical Care Options and NAM Selected by the International AIDS Society to Collaborate on Official Online Conference Coverage From Annual Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... It’s no secret that aging ... to a host of health issues, including urinary incontinence. However, results published in ... that good overall muscle strength in older women, particularly in the abdominal and ...
(Date:2/27/2017)... ... , ... The threat of nuclear warfare has long plagued this world. In ... underground testing of nuclear weapons. Years later, when her co-workers began dying, Dot started ... Nuclear Testing,” Clayton exposes the critical decisions made by agencies involved in the nuclear ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... POUGHKEEPSIE, N. ... ) has disclosed that despite scientific studies, the Center for Disease Control ( CDC ... Lyme disease . Kenneth B. Liegner, M.D. has compiled into a single volume ...
(Date:2/27/2017)... ... February 27, 2017 , ... New Jersey ranks among the top ... and genders. And the need for advanced services is growing. , Project WE ... care program, in collaboration with their non-profit partners in their fight against cancer and ...
(Date:2/26/2017)... New York, New York (PRWEB) , ... February ... ... of luxury baby products for wholesale distribution in North America, today announced it ... established online sites. The company, which prides itself on crafting quality and unique ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Israel and TAMPA, Fla. , Feb. ... emerging medical device company focused on developing cerebral ... applauds the members of the FDA,s Circulatory System ... their acknowledgement of the need for cerebral protection ... "The statements shared by this FDA panel ...
(Date:2/27/2017)... Md. , Feb. 27, 2017  RegeneRx ... a clinical-stage drug development company focused on tissue ... licensee for RGN-137, GtreeBNT Co., Ltd., received a ... Phase 3 clinical trial design for RGN-137 to ... wound healing gel that incorporates Thymosin beta 4 ...
(Date:2/27/2017)... 27, 2017 A recent research report published ... market alone is expected to reach a value of $55.8 billion ... along with 28 states have legalized marijuana for medical uses. In ... Florida , North Dakota , ... to use the drug in medical applications such as chemotherapies and ...
Breaking Medicine Technology: